A new drug currently being tested at the University of Virginia promises to do for women what Viagra has done for men. Suddenly, the year to come is looking a lot brighter to legions of undersexed people the nation over.
The drug, LibiGel, is a testosterone-based ointment that provides women with 24 hours of randiness after it is rubbed into the skin of the upper arm. While it is currently being prescribed only to women who have had both ovaries surgically removed, its manufacturers hope that it will one day be available to the roughly one-third of all American females who complain of having a low sex drive. The maker, BioSante Pharmaceuticals, recently received a $3.5 million cash infusion to facilitate development.
A 2004 clinical study of LibiGel showed that the drug “increased the number of satisfying sexual events by 238 percent,” from 2.1 to 7.1 events per month. If the drug never makes it to market, guys will be forced to hold out hope for something more along the lines of this. Which, you know, might be interesting. To some people.